Global Headlines: Screwworms, Trade Shifts, and Meds

Here are the four biggest U.S. and international stories as of Saturday, July 4, 2026.

First, the USMCA non-renewal announcement. On July 1, 2026, Donald Trump announced that he would not renew the United States-Mexico-Canada Agreement, known as the USMCA. This pact had served as the foundation of modern North American trade since 2020, replacing the North American Free Trade Agreement, or NAFTA. The USMCA was designed to regulate over $1.3 trillion in annual trade between the United States, Mexico, and Canada, an amount roughly equivalent to the gross domestic product of Australia. By refusing to renew the pact, Trump removed one of the last remaining formal structures governing the flow of goods and services across North America. The USMCA covers not just traditional goods, but also digital trade, intellectual property protections, and rules for the automotive, dairy, and pharmaceutical sectors. The pact includes labor and environmental standards, creating common ground for regulatory practices between the three countries. USMCA’s dispute resolution mechanisms provided a formal process for handling trade disagreements, which had helped minimize the risk of sudden tariffs or retaliatory barriers. These mechanisms were frequently used; for example, Canada and the U.S. recently resolved a dispute over dairy export quotas through the pact’s arbitration framework. Ending the USMCA eliminates these institutional safety nets.

Next, immediate economic reactions. The announcement of USMCA’s end sent immediate shockwaves through business, agriculture, and manufacturing sectors in all three countries. U.S. automotive manufacturers rely on cross-border supply chains to source components and assemble vehicles, with some cars crossing the U.S.-Mexico border as many as eight times before completion. The USMCA had set specific requirements for North American content in vehicles—such as mandating that 75% of a car’s parts be made in North America to qualify for zero tariffs. With the pact’s termination, those guarantees disappear, introducing the risk of new tariffs or import quotas. Mexico is a major exporter of agricultural products to the United States, including billions of dollars in fresh produce annually. U.S. farmers, in turn, export soybeans, corn, and pork to Mexico and Canada, benefiting from the tariff-free access established under the USMCA. The removal of the agreement’s protections means new tariffs or regulatory barriers could be imposed by any country on short notice, disrupting seasonal trade and eroding profit margins for farmers. U.S.-Canada trade in lumber, dairy, and energy is governed by detailed rules within the agreement; with those in doubt, commodity market volatility increases. For instance, the U.S. imported more than $350 billion in goods from Canada in the previous year, while Canada relied on the U.S. for over 70% of its total export market. Business leaders in all three countries expressed uncertainty about long-term investment planning, particularly in the automotive, pharmaceuticals, and electronics industries, which coordinate production on both sides of the borders. U.S.-based pharmaceutical manufacturers benefit from rules of origin and regulatory harmonization under the USMCA, reducing the cost of shipping drugs and medical devices. Without the pact, those companies now face the prospect of divergent rules and extra paperwork. Currency markets responded with fluctuations in the Mexican peso and Canadian dollar. Investors tend to react to increased uncertainty by pulling money out of markets perceived as riskier, which can lower the value of a country’s currency and make imports more expensive. Some multinational companies had contingency plans prepared in case the agreement lapsed, but others were caught off guard, having assumed that the framework would be renewed as a matter of course.

Now, shifting trade policy landscape. The removal of the USMCA as the continental trade platform means North America loses a key structure that supported supply chain resilience, job creation, and economic growth. Prior to the USMCA, NAFTA governed trade between the U.S., Mexico, and Canada from 1994 to 2020, and its replacement introduced new provisions to address digital commerce, labor rights, and environmental standards. No new trilateral trade framework exists as of July 4, 2026. Absent the USMCA, any new terms must be negotiated from scratch, a process that took years in past rounds of North American trade reform. Complex issues such as intellectual property protection, agricultural subsidies, and digital trade rules are now open for renegotiation or dispute. The United States, Mexico, and Canada may revert to World Trade Organization rules for cross-border commerce, which provide only basic levels of tariff protection and do not cover many sector-specific details. The pharmaceutical supply chain is one area especially vulnerable to fragmentation. USMCA provisions had supported the development of joint manufacturing facilities for generic and branded drugs, reducing dependency on suppliers outside North America. Losing that framework introduces new regulatory uncertainty and may affect public health security in the event of an emergency—such as a pandemic or a sudden surge in demand for a critical medication. North American supply chains for electronics, including semiconductors, rely on consistent rules for labor, safety, and environmental standards to coordinate cross-border production. The absence of a common framework increases operating costs by requiring companies to comply with separate compliance regimes in each country. The USMCA had also mandated rapid notification of new trade barriers, allowing companies to adjust to regulatory change. Losing that transparency increases the risk of sudden business disruptions. Agricultural exporters face renewed uncertainty over seasonal quotas and product standards. For example, U.S. apple growers in Washington state rely on Canadian and Mexican markets to absorb a third of their output each year; without the USMCA, phytosanitary rules or customs delays could easily disrupt this trade. American dairy producers, who gained access to new Canadian markets under the USMCA, may lose those opportunities if Canada imposes new import restrictions. Energy trade between the U.S. and Canada—worth tens of billions of dollars annually in oil, gas, and electricity—previously operated with minimal friction under the pact, but the end of the agreement removes that protection. The North American auto sector, which directly employs hundreds of thousands of workers, may see a slowdown in production investment or a shift in jobs if manufacturers decide to move assembly to locations with fewer trade obstacles. The uncertainty extends to e-commerce, as digital trade rules embedded in the USMCA had set standards for data flows, privacy, and cybersecurity. Without those, companies operating online marketplaces across borders face fragmented standards and potential new taxes. Policy analysts note that, as of July 4, 2026, no formal negotiations for a replacement agreement have been announced by any of the three countries.

Next, broader policy shifts. Recent news from July 1, 2026, highlights major developments in healthcare and education policy in the United States. In healthcare, a new era for GLP-1 medications is underway. GLP-1, or glucagon-like peptide-1, drugs are primarily prescribed for diabetes and weight management and are used by millions of Americans. The latest generation of GLP-1 medications has shown improved efficacy in controlling blood sugar and supporting weight loss compared to earlier drugs in the class. Healthcare spending in the United States is projected to grow more rapidly than the economy, with average annual growth in national health expenditures expected at 5.6% from 2023 to 2032. By 2032, health spending is projected to represent 19.7% of the entire U.S. GDP, up from 17.3% in 2022. The North American market for artificial intelligence in healthcare was valued at $14.66 billion in 2024, with expectations to reach over $250 billion by 2033, reflecting a compound annual growth rate of more than 37% from 2025 to 2033. This growth is fueled by the adoption of AI technologies for diagnostics, patient monitoring, and administrative tasks. The healthcare analytics market in North America was estimated at $20.9 billion in 2023 and is projected to expand at a CAGR of 19.6% through 2030, as more healthcare organizations turn to data-driven care models and predictive analytics. In education, student loan policy continues to evolve, affecting millions of borrowers nationwide. Recent updates on student loans aim to address both repayment burdens and access to higher education, though the specifics of new measures are still emerging. U.S. healthcare policy also faces challenges from the country’s relatively poor performance in population health compared to other wealthy nations. The United States exhibits higher prevalence rates for conditions like diabetes and alcohol-related incidents, which reduces average life expectancy and increases healthcare costs. Climate change is projected to worsen air quality, leading to higher rates of respiratory and cardiovascular disease. Vector-borne diseases, such as those carried by the Asian tiger mosquito, are expected to spread further into North America, raising the risk of outbreaks. The pharmaceutical supply chain’s stability is also threatened by the loss of USMCA-driven regulatory harmonization, increasing the risk of drug shortages or delays in accessing new treatments.

The Centers for Disease Control and Prevention reported a new outbreak of New World screwworm as of June 30, 2026. This parasite can infest livestock and humans, causing severe tissue damage and economic losses. The CDC issued public health alerts and containment measures to prevent the spread across state and national borders. The New World screwworm is a fly larva that, once established, can devastate cattle herds and wildlife populations. Outbreaks require rapid mobilization of animal health authorities, use of targeted insecticides, and, in some cases, the release of sterile flies to suppress the wild population. The last major outbreak in the U.S. cost the agriculture sector millions of dollars in control efforts before it was eradicated. The parasite’s ability to cross borders means that outbreaks quickly become a regional concern, threatening trade in livestock products and requiring coordinated response among the United States, Mexico, and Canada. This outbreak, coinciding with the end of USMCA, introduces additional complications for animal and public health authorities, as the trade pact had provided for streamlined cross-border emergency response protocols.

The most specific ripple from this convergence of trade and health policy is the risk to North America’s integrated pharmaceutical supply chains. The USMCA facilitated joint manufacturing and harmonized quality standards for generic and branded drugs, supporting economic resilience and public health security. With the agreement’s end, companies must now navigate three separate regulatory regimes. This change heightens the risk of delayed access to critical medications during emergencies, such as the New World screwworm outbreak reported by the CDC on June 30, 2026.